Abstract

The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDSrelated non-Hodgkin lymphoma and Multicentric Castlemans disease.

Keywords: AIDS, AIDS related Lymphoma, HAART, HIV, JC Polyoma virus associated progressive multifocal leukoencyphalopathy, Multicentric castleman's disease, non-hogdkin's lymphoma, rituximab, lymphoma, hepatitis B, hepatitis C, dose adjusted EPOCH, CHOP, CODOX-IVAC, magrath regimen, kaposi sarcoma, bortezomib